Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.73
- Piotroski Score 4.00
- Grade Buy
- Symbol (INSM)
- Company Insmed Incorporated
- Price $69.29
- Changes Percentage (1.76%)
- Change $1.2
- Day Low $67.42
- Day High $69.32
- Year High $80.53
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $74.50
- High Stock Price Target $95.00
- Low Stock Price Target $54.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.23
- Trailing P/E Ratio -10.87
- Forward P/E Ratio -10.87
- P/E Growth -10.87
- Net Income $-749,567,000
Income Statement
Quarterly
Annual
Latest News of INSM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The Chainsmokers want to bring a different kind of value add to B2B companies
The Chainsmokers, through their VC fund Mantis VC, aim to bring unique value to B2B startups beyond traditional VCs by leveraging their network and providing a different level of support and perspecti...
By TechCrunch | 4 days ago -
Do You Believe in the Growth Potential of Insmed (INSM)?
Baron Funds' "Baron Health Care Fund" Q3 2024 investor letter reveals a 5.81% gain compared to benchmarks. Highlighting Insmed Incorporated (NASDAQ:INSM), the biopharmaceutical company saw a one-month...
By Yahoo! Finance | 4 days ago -
Decoding Insmed Inc (INSM): A Strategic SWOT Insight
Insmed Inc faces potential financial challenges from market volatility and competition. Despite a strong balance sheet and robust product pipeline, operational losses persist due to high research and ...
By Yahoo! Finance | 4 days ago
